1. The subject of the contract is the supply of medicinal products under drug programmes – 5 TASKS.
1.1. The order was divided into parts:
TASK 1 - GLYCEROLI PHENYLBUTYRAS
ZADANIE 2 - NORMAL IMMUNOGLOBULINUM HUMANUM
TASK 3 - IMMUNOGLOBULINUM HUMANUM
ZADANIE 4 - NORMAL IMMUNOGLOBULIN HUMANUM
TASK 5 - ATALURENUM
1.2. OPTION – Within the scope of TASK 1, the Contracting Authority provides for the possibility of exercising the option under the conditions described in the Terms of Reference.
TASK 1 GLYCEROLA PHENYLBUTYRASThe subject of the contract is successive deliveries of medicinal products under drug programmes. The requirements concerning the subject matter of the contract and the terms of performance are contained in the annexes to the Terms of Reference, in particular Appendices No. 1, No. 2 and No. 3/1.
ZADANIE 2 NORMAL IMMUNOGLOBULINUM HUMANUMThe subject of the contract is successive deliveries of medicinal products under drug programmes. The requirements concerning the subject matter of the contract and the terms of implementation are contained in the annexes to the Terms of Reference, in particular Appendices No. 1, No. 2 and No. 3/2.
TASK 3 IMMUNOGLOBULINUM HUMANUMThe subject of the contract is successive deliveries of medicinal products under drug programmes. The requirements concerning the subject matter of the contract and the conditions of performance are included in the annexes to the Terms of Reference, in particular Appendices No. 1, No. 2 and No. 3/3.
ZADANIE 4 NORMAL IMMUNOGLOBULIN HUMANUMThe subject of the contract is successive deliveries of medicinal products under drug programmes. The requirements concerning the subject matter of the contract and the terms of implementation are included in the appendices to the Terms of Reference, in particular Appendices No. 1, No. 2 and No. 3/4.
TASK 5 ATALURENUMThe subject of the contract is successive deliveries of medicinal products under drug programmes. The requirements concerning the subject matter of the contract and the terms of implementation are included in the appendices to the Terms of Reference, in particular Appendices No. 1, No. 2 and No. 3/5.